Global Epidemiology of Drug-Resistant TB

Among regions with data available, parts of China and the former Soviet Union had the highest drug-resistance burden.

The Global Project on Anti-Tuberculosis Drug Resistance Surveillance, funded in part by Eli Lilly, has been active since 1994. To explore the latest trends in resistance, project researchers analyzed data from >90,000 patients in 83 countries and territories who received a diagnosis of pulmonary TB between 2002 and 2007. Drug-susceptibility results were quality assured by supranational reference laboratories.

Seventy-five countries and territories provided data on new TB cases. A median of 6.7% of such cases per country or territory were isoniazid (INH) resistant; in 17 settings, the prevalence of INH resistance was >15%. Although the median prevalence of multidrug-resistant (MDR) TB was 1.6%, the prevalence ranged from 0% in eight countries…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Global Epidemiology of Drug-Resistant TB

Topics

Reviewing Author